Nxera Pharma Co.,Ltd.
Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan
Filed with TSE ·
Watch Nxera Pharma's latest callNxera Pharma (Tokyo:4565) Q2 2026 Earnings Call · Replay · Aug 7Read the transcript of Nxera Pharma (Tokyo:4565) Q2 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Nxera Pharma Co., Ltd. on 6ix
Story so far
- Notice of Partial Forfeiture (Decrease in the Number of Shares to be Issued, etc.) in Connection with the Issuance of New Shares Under the RSU Plan
- Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award
- Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Earlier from Nxera Pharma
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets
- Nxera Announces Successful Resolution of miniG Patent Infringement Action
- Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
- Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
Later from Nxera Pharma
All Nxera Pharma news releasesFollow Nxera Pharma into a list and get an email when it puts out news.
Follow Nxera Pharma